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Introduction
Fibromatosis, also known as desmoid tumour, is a slow-growing and locally infiltrative 
disease caused by uncontrolled proliferation of fibrous tissue arising from deep 
musculoaponeurotic structures. It differs from fibrosarcoma by having low cellularity, 
infrequent mitoses, absence of necrosis, and not metastasising. Despite having benign 
histology, its aggressive local growth pattern can cause significant morbidity.1
 Fibromatosis is a rare entity, representing only 0.03% of all neoplasms.2 It is classified 
according to its anatomical position into abdominal, intra-abdominal, and extra-abdominal 
subtypes.1 Fibromatosis of the head and neck region comprises about 10 to 25% of all 
cases of extra-abdominal fibromatosis.3 Attempts have been made to separate it from that 
arising from other parts of the body because of the unique clinical problems it can cause 
in relation to its critical anatomical position.3-5
 The belief that cytotoxic chemotherapy is ineffective against slow-growing tumours 
with benign histology and is associated with significant morbidity has led to it being 
considered a last resort for patients who have run out of treatment options. We report a 
case where a woman whose fibromatosis of the neck obstructed her upper airway had a 
dramatic response to traditional chemotherapy.
Case report
A 40-year-old woman with a history of good past health first presented with a right 
neck swelling in May 2003. The neck mass was surgically excised and it was found to be 
a neurofibroma after examination by the pathologist. One year later, the neck swelling 
recurred and an incisional biopsy confirmed that it was caused by extra-abdominal 
fibromatosis. A computed tomographic (CT) scan showed a large soft tissue mass over 
her right lower neck, posterior to the right common carotid artery and jugular vein. She 
was given tamoxifen for 8 months. A later CT scan showed an enlarging tumour mass 
extending to the superior mediastinum and causing anterior displacement of the trachea. 
Her treatment was changed, tamoxifen was ceased and sulindac commenced but she 
developed an allergic reaction to sulindac. Debulking surgery was finally performed in 
2005, during which her right external carotid artery was ligated. She also developed right 
vocal cord palsy postoperatively.
 One year after the debulking surgery, the patient developed acute upper airway 
obstruction requiring an emergency procedure for airway relief. Intra-operatively, a 
huge right neck tumour was found tightly adherent to the prevertebral muscle. It closely 
surrounded the right common carotid artery and spread behind the trachea and oesophagus 
to the contralateral side. Inferiorly, the tumour reached the superior mediastinum. 
Exploratory sternotomy, debulking of the tumour, and a tracheostomy were performed. 
The right common carotid artery was ruptured during its dissection from the tumour and 
was ligated. A feeding jejunostomy was performed later to manage extrinsic oesophageal 
compression. A baseline CT scan of the neck was done after the operation (Fig 1).
 To manage her gross inoperable residual tumour, the patient was referred to the 
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楊美雲 Fibromatosis is a rare disease with benign histology. Its infiltrative growth pattern may prevent 
complete resection. We report a case of a 40-year-old woman with fibromatosis of the neck 
requiring an emergency operation for acute upper airway obstruction. Gross residual tumour 
was left behind but excellent tumour shrinkage was achieved by using weekly low-dose 
methotrexate and vinblastine. Despite the use of newer agents such as imatinib, cytotoxic 
chemotherapy remains an efficacious treatment for inoperable fibromatosis.
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纖維瘤是一種罕見的良性疾病。其浸潤性成長模式可避免病人完全切
除腫瘤。本文報告一名患有頸部纖維瘤的40歲女子，因急性上呼吸
道阻塞須接受急診手術。術後有明顯的腫瘤殘留，每週使用低劑量的
methotrexate及vinblastine後，腫瘤縮小。對於不能施行手術的纖維
瘤，雖然可使用如imatinib的新藥，可是細胞毒性化療仍是有效的療
法。
每週使用低劑量的methotrexate及vinblastine有
效醫治引致呼吸道阻塞的頸部纖維瘤
Kong, for possible radiotherapy, which has a 
documented role in the management of fibromatosis. 
Radiotherapy could not be justified, however, due to 
the exceptionally large radiotherapy portal required, 
making the risks of radiotherapy likely to outweigh 
any potential benefits. Thus, instead of stepping 
up local treatment, we managed her with low-dose 
chemotherapy using weekly methotrexate 50 mg and 
vinblastine 10 mg, both intravenously.
 After a few weeks of chemotherapy, the patient 
had a subjective improvement in neck tightness. Her 
obstructive symptoms improved gradually and she 
was able to resume oral feeding. The jejunostomy and 
tracheostomy tubes were removed after 6 months 
and 11 months, respectively. Her general condition 
and quality of life improved greatly.
 This response was also confirmed radiologically. 
Though the first CT scan performed after 2 months 
of chemotherapy showed minimal change, serial CT 
scans from 6 months onwards showed progressive 
improvement. Her most recent CT scan, performed 
after 16 months of chemotherapy, showed excellent 
tumour shrinkage amounting to a partial response 
according to the RECIST (Response Evaluation Criteria 
in Solid Tumours) scale (Fig 2).
 The patient did suffer side-effects, developing 
myelotoxicity with grade 3 neutropaenia after 6 weeks 
of chemotherapy. Her dose was halved and was well 
tolerated afterwards.
 It was planned that the total length of treatment 
be 12 months, but it was extended due to her 
continuing excellent response. Chemotherapy will 
be continued until a plateau of response is reached. 
The need for radiotherapy will be reviewed after 
maximal tumour shrinkage has been achieved.
Discussion
Fibromatosis of the head and neck is a rare disease. 
Patients usually present with a painless mass or less 
commonly, pain or neurological symptoms.4 Upper 
airway obstruction is a potentially fatal clinical 
presentation that requires urgent attention. As with 
fibromatosis arising from other parts of the body, 
surgical resection is the mainstay of treatment.1-6 The 
primary goal is to achieve a clear resection with wide 
margins, but preservation of function is of equal 
importance. Due to the complex anatomy and frequent 
entrapment of neurovascular structures in the head 
and neck region, these aims are often difficult to 
achieve. Resection often leads to injury of important 
surrounding tissues, for example the brachial plexus, 
and is associated with recurrence requiring repeated 
excisions.5 The reported recurrence rate ranges 
between 46 and 62%.5,6 The role of adjuvant therapy 
has not been established because of the occasional 
observation of spontaneous regression and arrested 
growth after incomplete excision, and the finding 
that the resection margin correlates poorly with the 
likelihood of local recurrence.4
 For patients with inoperable tumours, or 
those where surgery may result in major functional 
loss, radiotherapy is a reasonable option. Improved 
disease control has been reported in both adjuvant 
and primary settings.2,7,8 Primary radiotherapy has 
achieved a local control rate of up to 93%.8 The 
FIG 1. Computed tomographic scan before chemotherapy 
showing a huge tumour compressing the airway, vessels, and 
oesophagus after debulking surgery and tracheostomy
FIG 2. Computed tomographic scan after 16 months of 
chemotherapy showing excellent tumour shrinkage and 
removal of the tracheostomy tube
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optimal margin around the tumour, radiation dose, 
fractionation and technique remain undefined, with 
wide variations reported.7 Margins of 2 to 3 cm in 
transverse and 5 cm in longitudinal directions are 
commonly used, as in soft tissue sarcoma. Total doses 
ranging from 36.0 to 76.2 Gy have been reported.7 A 
dose-response relationship had been suggested with 
doses higher than 50 Gy being associated with better 
local control.2 Most authors propose a dose between 
50 and 60 Gy using conventional fractionation.
 Sulindac9 or other non-steroidal anti-
inflammatory drugs including celecoxib and 
hormonal therapy using tamoxifen10 or toremifene 
have shown promising disease control while causing 
fewer side-effects.
 Cytotoxic chemotherapy is usually reserved for 
patients in whom other treatment options have been 
exhausted. Many clinicians consider chemotherapy 
toxic and ineffective for low-grade tumours with 
a benign histology and no invasive component. 
While there are limited data on the use of single-
agent chemotherapy in fibromatosis, the overall 
response rate to combination chemotherapy ranges 
between 17 and 100% with a median response rate 
of 50%.11 Such an impressive level of responsiveness 
to chemotherapy is not demonstrated by other low-
grade tumours or even some malignant neoplasms. 
Commonly used regimens include doxorubicin-
based chemotherapy (doxorubicin with dacarbazine 
or doxorubicin with cyclophosphamide and 
vincristine), actinomycin D–based chemotherapy, or 
a combination of methotrexate with a vinca alkaloid 
(vinblastine or vinorelbine). These are all traditional 
agents that are cheap and easily available. The major 
concern about doxorubicin-based chemotherapy is 
cardiotoxicity while those related to actinomycin D–
based regimens include sterility and carcinogenesis. 
The combination of methotrexate with vinblastine, 
administered weekly, is associated with fewer side-
effects.12,13 This is a less toxic alternative, especially 
when the treatment has to be administered for 
prolonged periods. Fibromatosis usually responds 
slowly to chemotherapy; it may take months for the 
tumour to show a reduction in size. This may be due 
to the presence of mostly connective tissues with 
abundant collagen fibres, the low cellularity, and 
infrequent mitoses of this low-grade tumour. Current 
data support the use of chemotherapy for at least 1 
year unless there is evidence of disease progression 
or significant toxicity. Most patients can tolerate 
weekly low-dose methotrexate and vinblastine, 
although it was demonstrated that myelotoxicity 
and hepatotoxicity can lead to a prolonged interval 
between cycles.14 In our patient, myelotoxicity was 
managed effectively with a dose reduction, without 
compromising the treatment efficacy.
 Other alternatives to systemic treatment 
include biological agents such as interferon and 
more recently, imatinib, a tyrosine kinase inhibitor.15 
While the most effective therapeutic agent is yet to 
be defined, our patients should not be left without 
the option of cytotoxic chemotherapy just because of 
concerns about its toxicity or the misconception that 
it is not effective against low-grade tumours.
1.	 Enzinger	 FM,	Weiss	 SW.	 Soft	 tissue	 tumors:	 fibromatoses.	
4th	ed.	St	Louis,	MO:	Mosby;	2001.	
2.	 Nuyttens	 JJ,	Rust	PF,	Thomas	CR	 Jr,	Turrisi	AT	3rd.	Surgery	
versus	 radiation	 therapy	 for	 patients	 with	 aggressive	
fibromatosis	or	desmoid	tumors:	a	comparative	review	of	
22	articles.	Cancer	2000;88:1517-23.
3.	 Wang	 CP,	 Chang	 YL,	 Ko	 JY,	 Cheng	 CH,	 Yeh	 CF,	 Lou	
PJ.	 Desmoid	 tumor	 of	 the	 head	 and	 neck.	 Head	 Neck	
2006;28:1008-13.
4.	 Hoos	A,	 Lewis	 JJ,	Urist	MJ,	 et	 al.	Desmoid	 tumors	 of	 the	
head	and	neck—a	clinical	study	of	a	rare	entity.	Head	Neck	
2000;22:814-21.
5.	 Fasching	MC,	 Saleh	 J,	Woods	 JE.	 Desmoid	 tumors	 of	 the	
head	and	neck.	Am	J	Surg	1988;156:327-31.
6.	 Kulaylat	MN,	Karakousis	CP,	Keaney	CM,	McCorvey	D,	Bem	
J,	Ambrus	Sr	JL.	Desmoid	tumour:	a	pleomorphic	lesion.	Eur	
J	Surg	Oncol	1999;25:487-97.
7.	 Tolan	S,	Shanks	JH,	Loh	MY,	Taylor	B,	Wylie	JP.	Fibromatosis:	
benign	by	name	but	not	necessarily	by	nature.	Clin	Oncol	
(R	Coll	Radiol)	2007;19:319-26.
8.	 Spear	MA,	 Jennings	 LC,	Mankin	HJ,	 et	 al.	 Individualizing	
management	of	aggressive	fibromatoses.	Int	J	Radiot	Oncol	
Biol	Phys	1998;40:637-45.
9.	 Tsukada	K,	Church	 JM,	 Jagelman	DG,	et	al.	Noncytotoxic	
drug	therapy	for	intra-abdominal	desmoid	tumor	in	patients	
with	 familial	 adenomatous	 polyposis.	 Dis	 Colon	 Rectum	
1992;35:29-33.
10.	Chao	AS,	Lai	CH,	Hsueh	S,	Chen	CS,	Yang	YC,	Soong	YK.	
Successful	 treatment	 of	 recurrent	 pelvic	 desmoid	 tumour	
with	tamoxifen:	case	report.	Hum	Reprod	2000;15:311-3.
11.	Janinis	 J,	Patriki	M,	Vini	L,	Aravantinos	G,	Whelan	 JS.	The	
pharmacological	 treatment	 of	 aggressive	 fibromatosis:	 a	
systematic	review.	Ann	Oncol	2003;14:181-90.
12.	Weiss	AJ,	Lackman	RD.	Low-dose	chemotherapy	of	desmoid	
tumors.	Cancer	1989;64:1192-4.
13.	Skapek	 SX,	 Hawk	 BJ,	 Hoffer	 FA,	 et	 al.	 Combination	
chemotherapy	 using	 vinblastine	 and	methotrexate	 for	 the	
treatment	of	progressive	desmoid	tumor	in	children.	J	Clin	
Oncol	1998;16:3021-7.
14.	Azzarelli	A,	Gronchi	AP,	Bertulli	R,	et	al.	Low-dose	chemo-
therapy	with	methotrexate	and	vinblastine	 for	patients	with	
advanced	aggressive	fibromatosis.	Cancer	2001;92:1259-64.
15.	Chugh	 R,	 Maki	 RG,	 Thomas	 DG,	 et	 al.	 A	 SARC	 phase	
II	 multicenter	 trial	 of	 imatinib	 mesylate	 (IM)	 in	 patients	
with	aggressive	fibromatosis	 [abstract	9515].	 J	Clin	Oncol	
2006;24(18	Suppl):523S.
References
